4/15/2016

Reserpine Oral Tablets

Products Affected - Description

- Reserpine oral tablet, Sandoz, 0.1 mg, 100 count, NDC 00185-0032-01
- Reserpine oral tablet, Sandoz, 0.1 mg, 1000 count, NDC 00185-0032-10
- Reserpine oral tablet, Sandoz, 0.25 mg, 100 count, NDC 00185-0134-01
- Reserpine oral tablet, Sandoz, 0.25 mg, 1000 count, NDC 00185-0134-10

Reason for the Shortage

- Sandoz has discontinued reserpine.
- There are no other manufacturers of reserpine tablets.

Estimated Resupply Dates

- Sandoz has discontinued all reserpine tablet presentations.

Updated

Updated April 15, 2016 by Michelle Wheeler, PharmD, Drug Information Specialist. Created November 16, 2012 by Michelle Wheeler, PharmD, Drug Information Specialist. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.